Combinatorial therapies show synergy: NP@ESCu paired with αPD-L1 reduces tumor growth in preclinical HNSCC models by increasing PD-L1 expression and anti-tumor immunity, and Disulfiram overcomes resistance to multiple chemotherapeutics via ROS modulation [104,107]. Here, CD274 is linked to neoplasm.